Physician profile
Thomas E Oliveira
NPI 1124291828
$1,925.76
in general payments reported to CMS, 2019-2025
19 companies · $364 in 2025
The $364 reported for 2025 was more than what 79% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $56.28 · 2020: $356 · 2021: $488 · 2022: $330 · 2023: $246 · 2024: $83.88 · 2025: $364.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $695.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $694.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $498.16 | 2023-2025 | Repatha, Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $462.26 | 2021-2023 | |
| Pfizer INC. | $374.18 | 2019-2021 | |
| Abbott Laboratories | $115.33 | 2021-2023 | Freestyle Libre 3 |
| Astellas Pharma US INC | $85.00 | 2021 | |
| Lilly USA, LLC | $73.56 | 2020-2023 | Mounjaro, Trulicity |
| Janssen Pharmaceuticals, INC | $52.01 | 2020-2021 | |
| Amarin Pharma, INC. | $41.94 | 2020 | |
| Novo Nordisk INC | $36.99 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $36.95 | 2020 | |
| Bausch Health US, LLC | $23.07 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $21.83 | 2021 | |
| Si-Bone, INC. | $20.70 | 2023 | |
| Intra-Sana Laboratories | $19.53 | 2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Corcept Therapeutics | $17.66 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $16.60 | 2024 | |
| Genentech USA, INC. | $16.00 | 2020 | |
| Exact Sciences Corporation | $13.99 | 2025 | Cologuard Collection Kit |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Oliveira listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.